Ordering

How to Order

To order molecular testing and/or AccuCEA™ and specimen storage, download a requisition form

  • Molecular-only Test Results
    PanDNA test requisition available upon request
  • Include Patient Billing Demographic sheet and EUS report.
  • Ship specimen using provided kit with frozen shipping blocks.
  • Specimens will reside in storage at Interpace Diagnostics for up to 45 days.
  • If ordering molecular testing, please also include cytology, CEA, and amylase reports (if NOT tested by Interpace Diagnostics)
  • Fax Requisition form and clinical reports to Interpace Diagnostics at 888-674-6894

Turnaround Time

Expect a PancraGEN™ report delivered within 10 to 14 business days from the date of the requisition form (and sample, if applicable) submission.

Easy to Use

  • With AccuCEA™ streamline your diagnostic practice with this highly specialized CEA assay for Pancreatic Cysts only requiring 200uL of fluid; reflex to PancraGEN molecular testing as needed.
  • Comprehensive services including cytopathology, AccuCEA, storage, and molecular testing with a single sample (600ul).
  • Results Reports that are easy to read, conveniently delivered through our online portal.
  • Customer service and in-servicing for your office are available.
  • Patient financial assistance available through our Compass program.

Interpace Diagnostics Directory of Services

Download

International
Ordering

TAP Molecular Testing is the international distributor for all Interpace Diagnostics molecular tests.

Learn More

AccuCEA™

AccuCEA is our highly accurate CEA method designed specifically for pancreatic cyst fluids and is especially convenient when used with PancraGEN.

  • The only CEA assay validated for use on small volumes (200uL) of cyst fluid.
  • Delivers accurate CEA measurements on pancreatic cyst fluids
  • Offers physicians more options – reserve cyst fluid for other diagnostic tests
  • Results reported within 1-3 business days

Limitations and Disclaimers1

Although PancraGEN is highly specific for malignancy, some malignant cysts may not be detected. There may also be individuals who are falsely identified as having a malignant cyst. Diagnosis and appropriate patient management are the responsibility of the referring physician or health care provider.

References

  1. Al-Haddad MA, Kowalski T, Siddiqui A, et al. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. Endoscopy. 2015;47(2):136-146.
  2. V. Chernyak et al, Incidental pancreatic cystic lesions Radiology 2015 274 161-9
  3. BU Wu, et al, Prediction of malignancy in cystic neoplasms of the pancreas: a population based cohort study, Am J Gastro 2014 109 121-9
  4. Loren D, Kowalski T, Siddiqui A, et al. Influence of integrated molecular pathology test results on real-world management decisions for patients with pancreatic cysts: analysis of data from a national registry cohort. Diagnostic Pathology. 2016;11:5. doi:10.1186/s13000-016-0462-x.
  5. Gaujoux S., , Brennan, M., et al. Cystic Lesions of the Pancreas: Changes in the Presentation and Management of 1,424 Patients at a Single Institution over a 15-year Time Period. J Am Coll Surg. 2011 April; 212(4): doi:10.1016/j.jamcollsurg.2011.01.016.
  6. Kaimalkliotis, P., Riff, B., et al. Sendai and Fukuoka Consensus Guidelines Identify Advanced Neoplasia in Patients With Suspected Mucinous Cystic Neoplasms of the Pancreas. Clinical Gastroenterology and Hepatology 2015;13:1808–1815: doi:10.1016/j.cgh.2015.03.017
  7. Kushnir VM, Mullady DK, Das K, et al. J Clin Gastroenterol. 2019;53(9):686-692. DOI: 10.1097/MCG.0000000000001118.
  8. Gonda TA, Viterbo D, Gausman V, et al. Clin Gastroenterol Hepatol. 2017;15:913-919.